Apollon Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.2M Buy
38,595
+9,400
+32% +$4.38M 0.28% 79
2025
Q4
$13.2M Sell
29,195
-171
-0.6% -$73.7K 0.23% 91
2025
Q3
$11.5M Sell
29,366
-391
-1% -$163K 0.2% 98
2025
Q2
$13.2M Buy
29,757
+4,630
+18% +$2.13M 0.26% 73
2025
Q1
$12.2M Buy
25,127
+12,955
+106% +$6.04M 0.27% 76
2024
Q4
$4.9M Buy
12,172
+3,976
+49% +$1.84M 0.11% 160
2024
Q3
$3.81M Buy
8,196
+793
+11% +$381K 0.11% 166
2024
Q2
$3.47M Buy
7,403
+313
+4% +$136K 0.11% 173
2024
Q1
$2.96M Buy
7,090
+730
+11% +$309K 0.09% 201
2023
Q4
$2.59M Buy
6,360
+1,435
+29% +$530K 0.09% 207
2023
Q3
$1.71M Buy
4,925
+378
+8% +$132K 0.09% 227
2023
Q2
$1.6M Buy
4,547
+116
+3% +$39.1K 0.08% 264
2023
Q1
$1.4M Sell
4,431
-231
-5% -$69.3K 0.09% 244
2022
Q4
$1.35M Buy
4,662
+711
+18% +$217K 0.1% 224
2022
Q3
$1.14M Buy
3,951
+598
+18% +$172K 0.09% 221
2022
Q2
$945K Buy
3,353
+357
+12% +$95.6K 0.08% 274
2022
Q1
$782K Buy
2,996
+551
+23% +$131K 0.06% 347
2021
Q4
$537K Buy
+2,445
New +$475K 0.04% 444
2020
Q3
Sell
-16
Closed -$5K 671
2020
Q2
$5K Buy
+16
New +$4.34K ﹤0.01% 569

Other funds holding VRTX

Apollon Wealth Management's VRTX Position: Q1 2026 in Review

Apollon Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 32% in Q1 2026, buying an estimated $4.38M and bringing the position to 38,595 shares worth $17.2M. The position accounts for 0.28% of the portfolio, ranked #79.

Apollon Wealth Management first reported a position in VRTX in Q2 2020 and has held it in 19 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Apollon Wealth Management held 38,595 shares of Vertex Pharmaceuticals worth $17.2M as of Q1 2026.
  • Apollon Wealth Management bought 9,400 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.38M.
  • Vertex Pharmaceuticals made up 0.28% of Apollon Wealth Management's portfolio in Q1 2026, its #79 holding.
  • Apollon Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Apollon Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.